Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Industry Must Take Phase IV “Seriously,” Commissioner Tells PhRMA

Executive Summary

Pharmaceutical manufacturers need to step up their commitment to postmarketing surveillance and studies, FDA Commissioner McClellan told the Pharmaceutical Research & Manufacturers of America March 28 in Naples, Fla
Advertisement

Related Content

Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA
FDA Minds DTC “Reminder Ad” Increase, Seeks Better “Brief Summaries”
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
FDA Labeling Reform Will Trim Adverse Event Section, Temple Says
Pharmacogenomics Moves Into Spotlight With Completion Of Genome Project
Medicare Rx Funding Will Exceed $400 Bil., Breaux Predicts; War No Obstacle
DTC Guidance Is High Priority In First Amendment Review, FDA Says
FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
Advertisement
UsernamePublicRestriction

Register

PS041540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel